“…While developing these autoantibodies for cardioprotective effects for the α 1A -AR may be tempting, they may not be regulated by the normal desensitization and negative feedback mechanisms common in GPCRs to turn off or wane the signal, resulting in abnormal and non-physiological signaling and proliferation (Zhou et al, 2008;Karczewski et al, 2018;Becker et al, 2019;Wallukat et al, 2020). This abnormal signaling and proliferation may account for the vascular damage that many autoantibodies also impart (Zhou et al, 2008;Karczewski et al, 2012Karczewski et al, , 2018Becker et al, 2019;Wallukat et al, 2020). Autoantibodies against the α 1 -AR have also been associated with coronary heart disease (Thyrian et al, 2018), cardiac remodeling and dysfunction (Zhou et al, 2005;, pre-eclampsia (Ma et al, 2013), thromboangiitis obliterans (Buerger's Disease) (Klein-Weigel et al, 2014), AD and vascular dementia (Karczewski et al, 2012(Karczewski et al, , 2018Hempel et al, 2016), and prostate cancer (Wallukat et al, 2020).…”